Kura Oncology (NASDAQ:KURA) Cut to “Sell” at StockNews.com

StockNews.com lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

KURA has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Wednesday, November 13th. Wedbush reissued an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Trading Up 7.4 %

NASDAQ KURA opened at $10.80 on Wednesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $18.08 and a 200 day simple moving average of $19.76. Kura Oncology has a 12 month low of $9.06 and a 12 month high of $24.17. The firm has a market capitalization of $839.85 million, a P/E ratio of -4.66 and a beta of 0.86.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its holdings in Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares during the period. Sofinnova Investments Inc. grew its stake in Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after buying an additional 323,303 shares in the last quarter. Armistice Capital LLC raised its holdings in Kura Oncology by 14.7% during the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Kura Oncology during the first quarter worth $110,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.